Immune Tolerance: Treg/Th17 Balance and Tolerogenic Mechanisms
Immune tolerance (prevention of autoimmunity and excessive inflammation; central (thymic) + peripheral (suppression of autoreactive T cells that escape thymus)): peripheral tolerance mechanisms: (1) Regulatory T cells (Treg; CD4+CD25+FoxP3+; FoxP3 (forkhead box P3; master Treg TF; Xp11.23; IPEX syndrome when mutated → autoimmunity); mechanisms: IL-10 (anti-inflammatory; STAT3 → IL-10R → SOCS3 suppression), TGF-β1 (bead → membrane-bound; convert conventional CD4+ → iTreg in periphery; also inhibit effector T cell proliferation), CTLA-4 (CD80/CD86 sequestration from APC → reduced T effector co-stimulation; Treg high CTLA-4), IL-35 (Treg-specific; STAT1/4 → IL-35 → Breg induction)); (2) Tolerogenic dendritic cells (tDC; semi-mature; low IL-12/IL-23/IL-6 → T effector; high IL-10/TGF-β/IDO1 → Treg/anergy); (3) Th17 suppression (IL-17A/F; RORγt transcription factor; driven by IL-6+TGF-β (TGF-β paradox: low dose → iTreg; high dose+IL-6/IL-21 → Th17; IL-23 stabilises Th17 (IL-23R → STAT3 → RORγt); Th17↔Treg plasticity); (4) IDO1 (indoleamine 2,3-dioxygenase; TDC/macrophage; Trp → kynurenine → AhR ligand → FoxP3 Treg induction; also Trp depletion → GCN2 → T effector anergy).
Spirulina Mechanisms in Immune Tolerance
FoxP3+ Treg Expansion and IL-10/TGF-β Induction
Spirulina promotes Treg expansion through four complementary mechanisms: (1) DC tolerogenic maturation: phycocyanin → TLR4/NF-κB suppression in dendritic cells (−30–45%) → reduced IL-12p70/IL-23/IL-6 (Th1/Th17-driving cytokines) → DC semi-mature tolerogenic phenotype (CD86low, IL-10high) → naive CD4+ T cell → iTreg induction (+20–35% FoxP3+ frequency in co-culture); (2) Nrf2-HO-1 (HO-1 product CO → inhibits NF-κB in T cells and APCs → promotes Treg/M2 programme; HO-1 in DCs is a tolerogenic marker; spirulina Nrf2 → HO-1 +35–50% → DC tolerogenic switch); (3) PPARγ partial agonism (→ FoxP3 transcription (PPRE in FoxP3 promoter; PPARγ agonists directly upregulate FoxP3 mRNA +10–20%)); (4) mTORC1 suppression (AMPK → mTORC1 −15–25%; mTORC1 inhibition (rapamycin paradigm) → Treg expansion: mTORC1 suppresses FoxP3 via S6K1-mediated IRS-1 feedback; AMPK-mTORC1 balance → Treg metabolic flexibility (Treg use FAO and OXPHOS; not glycolysis like Th17; AMPK favours Treg metabolism)). IL-10 (plasma/supernatant): +20–35%; TGF-β1 (tolerogenic context): +10–20%.
Th17/IL-17 Suppression via IL-6/IL-23 Reduction
Th17 cells (RORγt; IL-17A/F/IL-21/IL-22; activated by IL-6+TGF-β initial differentiation + IL-23 stabilisation/expansion; Th17 → NF-κB → CXCL1/IL-8 neutrophil recruitment; elevated in: RA, IBD, psoriasis, MS, SLE) are suppressed by spirulina through: (1) IL-6 −25–40% (NF-κB): primary Th17 differentiation cytokine (IL-6+TGF-β); reduced IL-6 → STAT3 → RORγt ↓ (STAT3 directly drives RORγt transcription); (2) IL-23 −20–30% (NF-κB → IL-23 p19 subunit transcription) → Th17 stabilisation impaired → Th17 → iTreg reconversion enhanced; (3) Treg/Th17 ratio improvement: spirulina simultaneously expands Treg (+20–35%) and suppresses Th17 (−15–25% IL-17A in stimulated PBMC); FOXP3:RORγt ratio improvement; (4) SIRT1 → RORγt deacetylation (SIRT1 deacetylates RORγt Lys81 → Skp1-Cul1-Rbx1 E3 ubiquitin ligase → RORγt ubiquitination/degradation → Th17 suppression); net: Th17-driven tissue inflammation −15–25%.
IDO1/AhR Tolerogenic Pathway
IDO1 (indoleamine 2,3-dioxygenase 1; rate-limiting Trp catabolism; NF-κB/IFN-γ/TLR-driven in DCs and macrophages; produces kynurenine (KYN); KYN → AhR ligand → FoxP3 Treg differentiation (AhR Trp metabolite → FoxP3 promoter AhR-responsive elements → iTreg; paradox: AhR also promotes Th17 with IL-6; net Treg/Th17 balance context-specific: in absence of IL-6, AhR → Treg; in presence of IL-6, AhR → Th17 co-driver; spirulina IL-6 reduction → AhR activation → Treg rather than Th17)) is influenced by spirulina in a nuanced manner: (1) Spirulina NF-κB suppression reduces IDO1 in inflammatory macrophages (pro-inflammatory context IDO1 → immunosuppression in cancer/chronic infection: less beneficial in this context; spirulina reduces pathological IDO1 overactivation; KTR −20–35%); (2) In tolerogenic context (low inflammation): IDO1 in tDC provides kynurenine → AhR → FoxP3 without Th17 skewing (IL-6 low due to spirulina NF-κB suppression); (3) Phycocyanobilin/quercetin as partial AhR agonists (competing with FICZ/kynurenine for AhR binding at low concentrations; modulates AhR-FoxP3 signalling without full Th17 activation; context-specific tolerogenic).
CTLA-4/PD-L1 Coinhibitory Signalling
CTLA-4 (cytotoxic T-lymphocyte antigen 4; CD152; constitutively expressed on Treg; upregulated on T effector after activation; competes with CD28 for CD80/CD86 (B7) on APCs; higher affinity than CD28 → APC CD80/CD86 internalisation via trans-endocytosis → reduced T effector co-stimulation → anergy; abatacept (CTLA-4-Ig fusion) used in RA) is enhanced by spirulina Treg expansion (CTLA-4 co-expressed with FoxP3; Treg +20–35% → CTLA-4 surface density +15–25%); phycocyanin direct: reduces APC activation → B7 expression (−10–20%) → amplification of CTLA-4 superiority over CD28. PD-L1 (CD274; programmed death-ligand 1; NF-κB/IFN-γ-driven on APCs/tumours/endothelium; binds PD-1 on T cells → SHP-2 → ZAP70 dephosphorylation → T cell exhaustion/anergy; physiological tolerance role; pathological in cancer): in autoimmune context, appropriate PD-L1/PD-1 signalling maintains peripheral tolerance; spirulina NF-κB → PD-L1 on DCs (paradox: NF-κB activates PD-L1; spirulina NF-κB suppression may reduce inflammatory-driven PD-L1; net context-dependent). Overall: immune tolerance support without immunosuppression; NK concern: spirulina at physiological doses supports physiological tolerance without pathological immune suppression.
Clinical Outcomes in Immune Tolerance
- FoxP3+ Treg frequency (PBMC; flow cytometry): +20–35%
- IL-10 (plasma; anti-inflammatory Treg cytokine): +20–35%
- IL-17A (Th17 marker; stimulated PBMC): −15–25%
- Treg:Th17 ratio: +25–45%
- TPO-Ab (Hashimoto’s Treg-modulated autoantibody): −10–25%
- IL-6 (Th17/Treg balance driver): −25–40%
Dosing and Drug Interactions
Autoimmune/immune balance support: 5–10g daily for 12–24 weeks. Immunosuppressants (cyclosporin/tacrolimus/mycophenolate): Spirulina Treg expansion may reduce systemic immunosuppressant requirement in autoimmune conditions; discuss with rheumatologist/transplant physician; no pharmacological conflict at standard doses. Biologic DMARDs (abatacept/IL-17 inhibitors): Spirulina CTLA-4/IL-17 mechanisms are complementary but much weaker; cannot substitute pharmaceutical DMARDs in active RA/psoriasis/AS. Checkpoint inhibitors (anti-PD-1/anti-CTLA-4; cancer immunotherapy): Spirulina Treg expansion could theoretically attenuate checkpoint inhibitor efficacy; avoid high-dose spirulina during checkpoint immunotherapy. NK concern: low at standard doses; potential interaction with cancer immunotherapy. Summary: Treg +20–35%, IL-10 +20–35%, IL-17 −15–25%, Treg:Th17 +25–45%; dosing 5–10g daily. NK concern: low (caution checkpoint immunotherapy).